Cytoskeletal Vimentin Directs Cell‐Cell Transmission of Hepatitis C Virus
Source abstract
Abstract
Abstract Hepatitis C virus (HCV) is a major human pathogen causing liver diseases. Although direct‐acting antiviral agents effectively inhibit HCV infection, cell–cell transmission remains a critical venue for HCV persistence in vivo. However, the underlying mechanism of how HCV spreads intercellularly remains elusive. Here, we demonstrated that vimentin, a host intermediate filaments protein, is dispensable for HCV infection in cell models but essential for simulated in vivo infection in differentiated hepatocytes. Genetic removal of vimentin markedly and specifically disrupts HCV cell–cell transmission without influencing cell‐free infection. Through mutual co‐immunoprecipitation screening, we identified that the N‐terminal 1–95 amino acids of vimentin exclusively interact with the HCV envelope protein E1. Introducing either full‐length or head region of vimentin is capable of restoring the cell–cell transmission deficiency in vimentin‐knockout cells. Moreover, we showed that it is vimentin on the plasma membrane of recipient cells that orchestrates HCV cell–cell transmission. Consequently, vimentin antibody, either applied individually or in combination with HCV neutralizing antibody, exerts pronounced inhibition of HCV cell–cell transmission. Together, the results unveil an unrecognized function of vimentin as a unique venue dominating viral transmission, providing novel insights into propelling advancements in vimentin‐targeted anti‐HCV therapies.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Monoclonal and Polyclonal Antibodies Research · Toxin Mechanisms and Immunotoxins · T-cell and B-cell Immunology
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
University of Chinese Academy of Sciences Yuquan Road No. 19(A) Shijingshan District Beijing 100049 P. R. China
Key Laboratory of Molecular Virology and Immunology Shanghai Institute of Immunity and Infection Chinese Academy of Sciences Shanghai 200031 P. R. China
Funding
National Natural Science Foundation of China · Natural Science Foundation of Shanghai Municipality · Program of Shanghai Academic Research Leader
References (58)
Show source-provided references
1. 10.1128/JVI.00443-1010.1128/JVI.00443-10 ↗
2. 10.1016/j.coviro.2012.11.00410.1016/j.coviro.2012.11.004 ↗
3. 10.1128/JVI.78.21.11980-11987.200410.1128/JVI.78.21.11980-11987.2004 ↗
4. 10.1371/journal.ppat.100263410.1371/journal.ppat.1002634 ↗
5. 10.1016/j.jhep.2012.09.02210.1016/j.jhep.2012.09.022 ↗
6. 10.3748/wjg.v13.i17.243610.3748/wjg.v13.i17.2436 ↗
7. 10.7150/ijms.3.2910.7150/ijms.3.29 ↗
8. 10.1002/hep.2195910.1002/hep.21959 ↗
9. 10.1371/journal.ppat.100412810.1371/journal.ppat.1004128 ↗
10. 10.1128/JVI.01592-1010.1128/JVI.01592-10 ↗
11. 10.1002/hep.2469210.1002/hep.24692 ↗
12. 10.1371/journal.pone.006422110.1371/journal.pone.0064221 ↗
13. 10.1038/nbt.317910.1038/nbt.3179 ↗
14. Fan H. · J. Virol. · 2017 · 91 · 1128
15. 10.1111/micc.1211110.1111/micc.12111 ↗
16. 10.1146/annurev-cellbio-100617-06253410.1146/annurev-cellbio-100617-062534 ↗
17. 10.3390/ijms2113467510.3390/ijms21134675 ↗
18. 10.1242/jcs.26050910.1242/jcs.260509 ↗
19. 10.1038/s41467-023-36123-w10.1038/s41467-023-36123-w ↗
20. 10.1016/j.ceb.2023.10231710.1016/j.ceb.2023.102317 ↗
21. 10.1242/jcs.25059710.1242/jcs.250597 ↗
22. 10.1073/pnas.211390911910.1073/pnas.2113909119 ↗
23. 10.1016/j.virusres.2011.06.00110.1016/j.virusres.2011.06.001 ↗
24. 10.1186/s12929-016-0234-710.1186/s12929-016-0234-7 ↗
25. 10.3390/ijms2214746910.3390/ijms22147469 ↗
26. 10.1073/pnas.211387411910.1073/pnas.2113874119 ↗
27. 10.1016/j.isci.2022.10546310.1016/j.isci.2022.105463 ↗
28. 10.1038/s41598-022-11248-y10.1038/s41598-022-11248-y ↗
29. 10.1002/smll.20210564010.1002/smll.202105640 ↗
30. 10.1021/acsami.3c0334710.1021/acsami.3c03347 ↗
31. 10.1128/JVI.00307-1710.1128/JVI.00307-17 ↗
32. 10.1155/2015/42781410.1155/2015/427814 ↗
33. 10.1128/JVI.01059-0610.1128/JVI.01059-06 ↗
34. 10.1126/science.abn988410.1126/science.abn9884 ↗
35. 10.1016/j.semcancer.2021.12.00610.1016/j.semcancer.2021.12.006 ↗
36. 10.1111/j.1349-7006.2006.00161.x10.1111/j.1349-7006.2006.00161.x ↗
37. 10.2174/15665241279837615210.2174/156652412798376152 ↗
38. 10.1093/ve/vead01710.1093/ve/vead017 ↗
39. 10.1371/journal.ppat.100974610.1371/journal.ppat.1009746 ↗
40. 10.1084/jem.2003064810.1084/jem.20030648 ↗
41. 10.1016/j.tim.2015.02.00310.1016/j.tim.2015.02.003 ↗
42. 10.1371/journal.ppat.100475110.1371/journal.ppat.1004751 ↗
43. 10.1128/JVI.03306-1410.1128/JVI.03306-14 ↗
44. 10.1038/ncb168210.1038/ncb1682 ↗
45. 10.1128/JVI.00090-1810.1128/JVI.00090-18 ↗
46. 10.1073/pnas.211140011910.1073/pnas.2111400119 ↗
47. 10.1091/mbc.E18-04-022810.1091/mbc.E18-04-0228 ↗
48. 10.1128/mBio.00160-1810.1128/mBio.00160-18 ↗
49. 10.1002/pmic.20040109310.1002/pmic.200401093 ↗
50. 10.1111/j.1365-2893.2011.01487.x10.1111/j.1365-2893.2011.01487.x ↗
51. 10.1016/j.virol.2008.10.00910.1016/j.virol.2008.10.009 ↗
52. 10.1371/journal.pone.014208210.1371/journal.pone.0142082 ↗
53. 10.1073/pnas.050359610210.1073/pnas.0503596102 ↗
54. 10.1128/JVI.01307-0610.1128/JVI.01307-06 ↗
55. Zhao Y. · J. Virol. · 2018 · 92 · 10
56. 10.1126/sciadv.abd973210.1126/sciadv.abd9732 ↗
57. 10.1016/j.virusres.2010.11.00910.1016/j.virusres.2010.11.009 ↗
58. 10.1038/s41423-020-0403-110.1038/s41423-020-0403-1 ↗